Opioid agonist/antagonist combinations

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 7749542
APP PUB NO 20080292694A1
SERIAL NO

12220760

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
PURDUE PHARMA L.P.STAMFORD, CT439

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Colucci, Robert D Newtown, US 21 1744
Kaiko, Robert F Weston, US 47 2856

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (5)
5376662 Method of attenuating nerve injury induced pain 74 1993
2004/0092,542 Tamper-resistant oral opioid agonist formulations 54 2003
2005/0095,291 Tamper-resistant oral opioid agonist formulations 75 2003
2005/0181,046 Tamper-resistant oral opioid agonist formulations 68 2003
2006/0039,970 Tamper-resistant oral opioid agonist formulations 42 2003
 
NOVA PHARMACEUTICAL CORPORATION (2)
4760069 Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists 88 1985
4889860 Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists 95 1987
 
The Lynx Project Limited (1)
6310072 Production of analgesic synergy by co-administration of sub-analgesic doses of a MU opioid agonist and a kappa-2 opioid agonist 76 1997
 
VIRGINIA COMMONWEALTH UNIVERSITY (4)
5352683 Method for the treatment of chronic pain 128 1993
5321012 Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance 203 1993
5502058 Method for the treatment of pain 181 1994
5556838 Inhibiting the development of tolerance to and/or dependence on an addictive substance 178 1994
 
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (1)
5225440 Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase 81 1991
 
ELI LILLY AND COMPANY (1)
5998434 Composition for treating pain 67 1998
 
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (1)
4803208 Opiate agonists and antagonists 76 1985
 
ICN HUNGARY RT. (1)
5317022 Pharmaceutical composition and use 79 1992
 
G. D. Searle & Co. (1)
5616601 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation 169 1995
 
SCULLY SCOTT MURPHY & PRESSER, PC (1)
5426112 Growth regulation and related applications of opioid antagonists 142 1993
 
BAKER NORTON PHARMACEUTICALS, INC. (1)
4873076 Method of safely providing anesthesia or conscious sedation 90 1989
 
OMEROS CORPORATION (2)
5858017 Urologic irrigation solution and method for inhibition of pain, inflammation and spasm 134 1996
5860950 Arthroscopic irrigation solution and method for inhibition of pain and inflammation 122 1996
 
COLMAN PRODUCTS LIMITED (1)
4935428 Treating opiate dependence 103 1988
 
The Rockefeller University (3)
4987136 Method for controlling gastrointestinal dysmotility 146 1986
4769372 Method of treating patients suffering from chronic pain or chronic cough 166 1986
4785000 Method of treating patients suffering from chronic pain or chronic cough 115 1987
 
Adir et Compagnie (1)
5130311 Oxazolopyridine compounds, compositions and use 97 1991
 
Schaap; Robert J. (2)
5316759 Agonist-antagonist combination to reduce the use of nicotine and other drugs 103 1992
5574052 Agonist-antagonist combination to reduce the use of nicotine and other drugs 165 1994
 
E. I. DU PONT DE NEMOURS AND COMPANY (2)
4451470 Analgesic, antagonist, and/or anorectic 14-fluoromorphinans 90 1982
5593994 Prostaglandin synthase inhibitors 116 1994
 
BRISTOL-MYERS SQUIBB COMPANY (1)
4457933 Prevention of analgesic abuse 191 1981
 
DynaGen, Inc. (1)
5486362 Controlled, sustained release delivery system for treating drug dependency 139 1993
 
MERCK SHARP & DOHME LTD. (1)
5880132 Tachykinin antagonist and an opioid analgesic effective at treating pain or nociception 80 1997
 
WARNER-LAMBERT COMPANY LLC (1)
5149538 Misuse-resistive transdermal opioid dosage form 250 1991
 
THE UNIVERSITY OF CHICAGO (4)
4719215 Quaternary derivatives of noroxymorphone which relieve nausea and emesis 121 1986
4861781 Quaternary derivatives of noroxymorphone which relieve nausea and emesis 115 1987
5102887 Method for reducing emesis and nausea induced by the administration of an emesis causing agent 114 1990
5972954 Use of methylnaltrexone and related compounds 132 1997
 
UNITED BIOMEDICAL, INC. (2)
5633259 Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction 74 1995
5624932 Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction 73 1995
 
UNIVERSITY OF OREGON (1)
5514680 Glycine receptor antagonists and the use thereof 116 1993
 
MERCK FROSST COMPANY (1)
5474995 Phenyl heterocycles as cox-2 inhibitors 212 1994
 
CONTRAL CLINICS OY (3)
4882335 Method for treating alcohol-drinking response 100 1988
5096715 Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist 84 1989
5086058 Method for treating alcoholism with nalmefene 97 1990
 
ALZA CORPORATION (4)
4573995 Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine 180 1984
5236714 Abusable substance dosage form having reduced abuse potential 146 1988
5460826 Morphine therapy 163 1994
5866164 Composition and dosage form comprising opioid antagonist 263 1997
 
YOUNG, JACQUELINE, MS. (1)
5356900 Method of treating chronic herpes virus infections using an opiate receptor antagonist 78 1993
 
SIMON, DAVID L. (1)
6103258 Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics 70 1998
 
MERCK FROSST CANADA LTD. (10)
5409944 Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase 121 1993
5604260 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 140 1993
5436265 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents 139 1993
5521213 Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 147 1994
5552422 Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents 160 1995
5536752 Phenyl heterocycles as COX-2 inhibitors 137 1995
5550142 Phenyl heterocycles as cox-2 inhibitors 141 1995
5510368 N-benzyl-3-indoleacetic acids as antiinflammatory drugs 138 1995
5604253 N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors 128 1995
5639780 N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors 131 1995
 
EURO-CELTIQUE S.A. (35)
4366310 Controlled release compositions 102 1980
4443428 Extended action controlled release compositions 163 1982
4940587 Oral pharmaceutical composition through mucosa 131 1986
4844907 Pharmaceutical composition comprising analgesic and anti-inflammatory agent 159 1986
4834965 Controlled release pharmaceutical composition 116 1987
4867985 Spheroids 107 1988
5071646 Pharmaceutical ion exchange resin composition 162 1989
5091189 Controlled release dosage forms having a defined water content 62 1991
5215758 Controlled release matrix suppository for pharmaceuticals 138 1991
5324351 Aqueous dispersions of zein and preparation thereof 160 1992
5356467 Controlled release coatings derived from aqueous dispersions of zein 262 1993
5500227 Immediate release tablet cores of insoluble drugs having sustained-release coating 234 1993
5622722 Spheroid formulation 64 1994
5508043 Controlled release matrix for pharmaceuticals 87 1995
5670172 Pharmaceutical spheroid formulation 112 1995
6024982 Immediate release tablet cores of insoluble drugs having sustained-release coating 157 1995
5811126 Controlled release matrix for pharmaceuticals 154 1995
5763452 Pharmaceutical compositions and usages 60 1996
5849240 Method of preparing sustained release pharmaceutical compositions 220 1996
5891471 Pharmaceutical multiparticulates 183 1996
5601845 Pharmaceutical spheroid formulation 108 1996
5843480 Controlled release diamorphine formulation 147 1996
5879705 Sustained release compositions of morphine and a method of preparing pharmaceutical compositions 190 1997
5908848 Synergistic composition of codine and ibuprofen to treat arthritis 62 1997
5942241 Formulations and methods for providing prolonged local anesthesia 180 1997
6068855 Pharmaceutical composition containing a fusible carrier and method for producing the same 103 1997
5965163 Substained release compositions and a method of preparing pharmaceutical compositions 194 1997
6077532 Pharmaceutical ion exchange resin composition 69 1998
6306438 Stabilized sustained release tramadol formulations 114 1998
6399096 Pharmaceutical formulation 118 1998
6143328 Sustained release compositions and a method of preparing pharmaceutical compositions 84 1999
6162467 Sustained release compositions and a method of preparing pharmaceutical compositions 157 1999
6210714 Immediate release tablet cores of acetaminophen having sustained-release coating 116 2000
6387404 Immediate release tablet cores of insoluble drugs having sustained-release coating 132 2001
6627635 Method of preventing abuse of opioid dosage forms 168 2001
 
PURDUE PHARMA L.P. (40)
4828836 Controlled release pharmaceutical composition 234 1987
4834985 Controlled release pharmaceutical composition 247 1987
4990341 Controlled release hydromorphone composition 208 1989
5266331 Controlled release oxycodone compositions 299 1991
5273760 Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer 301 1991
5286493 Stabilized controlled release formulations having acrylic polymer coating 297 1992
5549912 Controlled release oxycodone compositions 291 1993
5472712 Controlled-release formulations coated with aqueous dispersions of ethylcellulose 287 1993
5478577 Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level 307 1993
5411745 Powder-layered morphine sulfate formulations 189 1994
5965161 Extruded multi-particulates 236 1994
5639476 Controlled release formulations coated with aqueous dispersions of acrylic polymers 597 1995
5508042 Controlled release oxycodone compositions 328 1995
5968551 Orally administrable opioid formulations having extended duration of effect 318 1995
5958459 Opioid formulations having extended controlled released 213 1995
5656295 Controlled release oxycodone compositions 277 1996
5681585 Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer 169 1996
5672360 Method of treating pain by administering 24 hour oral opioid formulations 281 1996
6143322 Method of treating humans with opioid formulations having extended controlled release 206 1997
5958452 Extruded orally administrable opioid formulations 283 1997
5968547 Method of providing sustained analgesia with buprenorphine 119 1997
6077533 Powder-layered oral dosage forms 93 1998
6228863 Method of preventing abuse of opioid dosage forms 260 1998
* 6277384 Opioid agonist/antagonist combinations 164 1998
6103261 Opioid formulations having extended controlled release 199 1999
6335033 Melt-extrusion multiparticulates 153 1999
6261599 Melt-extruded orally administrable opioid formulations 224 1999
6294195 Orally administrable opioid formulations having extended duration of effect 183 1999
6375957 Opioid agonist/opioid antagonist/acetaminophen combinations 266 2000
6696088 Tamper-resistant oral opioid agonist formulations 215 2001
6716449 Controlled-release compositions containing opioid agonist and antagonist 128 2001
* 6475494 Opioid agonist/antagonist combinations 142 2001
2003/0069,263 Pharmaceutical combinations of oxycodone and naloxone 84 2002
2003/0073,714 Opioid agonist formulations with releasable and sequestered antagonist 83 2002
* 6696066 Opioid agonist/antagonist combinations 194 2002
2003/0229,111 Naltrexone hydrochloride compositions 41 2003
2004/0186,121 Tamper-resistant oral opioid agonist formulations 65 2003
* 7172767 Opioid agonist / antagonist combinations 113 2003
2006/0182,801 Sequestered antagonist formulations 75 2006
* 7419686 Opioid agonist/antagonist combinations 69 2006
 
EUROCELTIQUE S.A., 122, BOULEVARD DE LA PETRUSSE, LUXEMBOURG (2)
4844909 Controlled release hydromorphone composition 201 1987
4844910 Spheroids 72 1987
 
McGinnis; Carolyn (1)
4608376 Opiate agonists and antagonists 72 1982
 
AMINOTEK SCIENCES, INC. A CORP. OF NEW JERSEY (1)
5256669 Methods and compositions for treating acute or chronic pain and drug addiction 80 1992
 
UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (1)
4464378 Method of administering narcotic antagonists and analgesics and novel dosage forms containing same 232 1981
 
PEPTECH (UK) LIMITED (1)
5534492 Muramyl peptide for the treatment of toxicity 69 1995
 
The United States of America as represented by the Secretary of the Army (1)
5834477 Opiate analgesic formulation with improved safety 64 1994
 
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (5)
5472943 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists 160 1993
5585348 Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia 102 1993
* 5580876 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 117 1995
6194382 Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists 78 1999
6765010 Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects 66 2002
 
RECKITT BENCKISER HEALTHCARE (UK) LIMITED (2)
4582835 Analgesic compositions 159 1984
4661492 Analgesic compositions 124 1985
 
GENERAL ELECTRIC COMPANY (1)
5226331 Apparatus and method for measuring the particle number rate and the velocity distribution of a sprayed stream 49 1991
 
RUTGERS, STATE UNIVERSITY OF NEW JERSEY, THE, OLD QUEEN BUILDING, SOMERSET AND GEORGE STREETS, NEW BRUNSWICK, NJ 08903 (1)
4806341 Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration 197 1986
 
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (6)
* 5512578 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists 130 1994
5767125 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 116 1996
6096756 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 144 1998
2001/0006,967 METHOD OF SIMULTANEOUSLY ENHANCING ANALGESIC POTENCY AND ATTENUATING ADVERSE SIDE EFFECTS CAUSED BY TRAMADOL AND OTHER BIMODALLY-ACTING OPIOID AGONISTS 54 1999
6362194 Method and simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 66 2000
6395705 Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists 74 2001
 
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (1)
4806543 Method and compositions for reducing neurotoxic injury 99 1986
 
REGENTS OF THE UNIVERSITY OF MINNESOTA (6)
4401672 Non-addictive narcotic antitussive preparation 84 1981
4730048 Gut-selective opiates 116 1985
5352680 Delta opioid receptor antagonists to block opioid agonist tolerance and dependence 132 1992
5457208 Kappa opioid receptor antagonists 95 1993
5578725 Delta opioid receptor antagonists 78 1995
5780479 Use of opioid antagonists to treat impulse-control disorders 73 1997
 
THE MCLEAN HOSPITAL CORPORATION (1)
5075341 Treatment for cocaine abuse 168 1989
 
Ortho-McNeil Pharmaceutical, Inc. (1)
5336691 Composition comprising a tramadol material and acetaminophen and its use 107 1992
 
NAPP PHARMACEUTICAL GROUP LIMITED (3)
5591452 Controlled release formulation 118 1994
6326027 Controlled release formulation 112 1995
6254887 Controlled release tramadol 121 1996
 
ENCINAL PHARMACEUTICAL INVESTMENTS, LLC (1)
5869097 Method of therapy comprising an osmotic caplet 97 1992
 
PURDUE PHARMA COMPANY, THE (2)
4861598 Controlled release bases for pharmaceuticals 272 1986
4970075 Controlled release bases for pharmaceuticals 234 1989
 
THE DUPONT MERCK PHARMACEUTICAL COMPANY (1)
4722928 N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes 42 1985
 
PUREUE PHARMA L.P. (1)
4834984 Controlled release dihydrocodeine composition 190 1987
 
LIFESHIELD SCIENCES LLC (1)
2004/0158,312 Braided endoluminal device having tapered filaments 24 2003
 
BASF AKTIENGESELLSCHAFT (2)
4806558 Diarylacetylenes and their use in treating acne 74 1985
4957681 Preparation of pharmaceutical mixtures 163 1989
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
RECRO GAINESVILLE LLC (4)
9132096 Abuse resistant pharmaceutical compositions 2 2014
9486451 Abuse resistant pharmaceutical compositions 0 2015
9452163 Abuse resistant pharmaceutical compositions 0 2015
9713611 Abuse resistant pharmaceutical compositions 0 2016
 
Other [Check patent profile for assignment information] (1)
9814710 Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome 0 2014
 
PURDUE PHARMA L.P. (28)
8518925 Opioids for the treatment of the chronic obstructive pulmonary disease (COPD) 6 2005
9101625 Buprenorphine-wafer for drug substitution therapy 1 2007
8987290 Use of opioid formulations in needle-less drug delivery devices 1 2007
* 2010/0056,554 USE OF OPIOID FORMULATIONS IN NEEDLE-LESS DRUG DELIVERY DEVICES 0 2007
9271940 Immediate release pharmaceutical compositions comprising oxycodone and naloxone 0 2010
* 8105631 Opioid agonist/antagonist combinations 43 2010
8673355 Opioid agonist/antagonist combinations 13 2011
8846090 Matrix for sustained, invariant and independent release of active compounds 15 2012
8822487 Opioid agonist/opioid antagonist/acetaminophen combinations 13 2012
8846091 Matrix for sustained, invariant and independent release of active compounds 14 2013
9084729 Abuse-resistant controlled-release opioid dosage form 3 2013
8969369 Abuse-resistant controlled-release opioid dosage form 15 2013
9056051 Abuse-resistant controlled-release opioid dosage form 5 2014
9205082 Opioid agonist/antagonist combinations 1 2014
9555000 Pharmaceutical preparation containing oxycodone and naloxone 1 2014
9474750 Opioid agonist/opioid antagonist/acetaminophen combinations 1 2014
9655855 Matrix for sustained, invariant and independent release of active compounds 1 2014
8936808 Opioid agonist/opioid antagonist/acetaminophen combinations 4 2014
8932630 Opioid agonist/antagonist combinations 4 2014
9168252 Abuse-resistant controlled-release opioid dosage form 2 2015
9161937 Abuse-resistant controlled-release opioid dosage form 3 2015
9283216 Abuse-resistant controlled-release opioid dosage form 1 2015
9283221 Abuse-resistant controlled-release opioid dosage form 1 2015
9358230 Abuse-resistant controlled-release opioid dosage form 1 2016
9345701 Abuse-resistant controlled-release opioid dosage form 1 2016
9763931 Buprenorphine-wafer for drug substitution therapy 0 2016
9511066 Abuse-resistant controlled-release opioid dosage form 1 2016
9480685 Abuse-resistant controlled-release opioid dosage form 1 2016
 
QRxPHARMA Ltd. (1)
* 8933092 Methods and compositions comprising sequential administration opioid receptor agonists 1 2012
 
RHODES PHARMACEUTICALS L.P. (1)
9370512 Buprenorphine-wafer for drug substitution therapy 1 2015
 
EGALET LTD. (10)
8877241 Morphine controlled release system 4 2004
9005660 Immediate release composition resistant to abuse by intake of alcohol 5 2010
9023394 Formulations and methods for the controlled release of active drug substances 4 2013
9694080 Polymer release system 0 2013
8808745 Morphine polymer release system 8 2013
9044402 Abuse-deterrent pharmaceutical compositions for controlled release 4 2014
9707179 Opioid polymer release system 0 2014
9642809 Controlled release pharmaceutical compositions for prolonged effect 0 2014
9375428 Morphine controlled release system 1 2014
9358295 Immediate release composition resistant to abuse by intake of alcohol 2 2015
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 6, 2018
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 6, 2022
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00